Differential sensitivity of human monocytes and macrophages to ANP: a role of intracellular pH on reactive oxygen species production through the phospholipase involvement.
Atrial natriuretic peptide (ANP), a cardiovascular hormone, elicits different biological actions in the immune system. The aim of the present work was to study the effect of ANP on the intracellular pH (pHi) of human monocytes and macrophages and to investigate whether pHi changes could play a role on phospholipase activities and reactive oxygen species (ROS) production. Human macrophages isolated by peripheral blood mononuclear cells and THP-1 monocytes, which were shown to express all three natriuretic peptide receptors (NPR-A, NPR-B, and NPR-C), were treated with physiological concentrations of ANP. A significant decrease of pHi was observed in ANP-treated macrophages with respect to untreated cells; this effect was paralleled by enhanced phospholipase activity and ROS production. Moreover, all assessed ANP effects seem to be mediated by the NPR-C. In contrast, no significant effect on pHi was observed in THP-1 monocytes treated with ANP. Treatment of macrophages or THP-1 monocytes with 5-(N-ethyl-N-isopropyl)amiloride, a specific Na(+)/H(+) antiport inhibitor, decreases pHi in macrophages and monocytes. Our results indicate that only macrophages respond to ANP in terms of pHi and ROS production, through diacylglycerol and phosphatidic acid involvement, pointing to ANP as a new modulator of ROS production in macrophages.
Baldini
P M
PM
Department of Biology, University of Rome Tor Vergata, Italy. Baldini@uniroma2.it
De Vito
P
P
Martino
A
A
Fraziano
M
M
Grimaldi
C
C
Luly
P
P
Zalfa
F
F
Colizzi
V
V
D000584:Amiloride / Q000031:analogs & derivatives* / Q000494:pharmacology; D000889:Anti-Arrhythmia Agents / Q000494:pharmacology; D009320:Atrial Natriuretic Factor / Q000494:pharmacology*; D002478:Cells, Cultured; D002855:Chromatography, Thin Layer; D017931:DNA Primers / Q000737:chemistry; D004075:Diglycerides / Q000378:metabolism; D006162:Guanylate Cyclase / Q000235:genetics / Q000378:metabolism; D006801:Humans; D006863:Hydrogen-Ion Concentration; D008264:Macrophages / Q000187:drug effects*; D009000:Monocytes / Q000187:drug effects*; D010712:Phosphatidic Acids / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D017382:Reactive Oxygen Species / Q000378:metabolism*; D017461:Receptors, Atrial Natriuretic Factor / Q000235:genetics / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012680:Sensitivity and Specificity; D017923:Sodium-Hydrogen Exchangers / Q000037:antagonists & inhibitors; D010738:Type C Phospholipases / Q000378:metabolism*; D000099242:Atrial Natriuretic Factor Receptor B
D000584:Amiloride; D000889:Anti-Arrhythmia Agents; D009320:Atrial Natriuretic Factor; D017931:DNA Primers; D004075:Diglycerides; D006162:Guanylate Cyclase; D010712:Phosphatidic Acids; D012333:RNA, Messenger; D017382:Reactive Oxygen Species; D017461:Receptors, Atrial Natriuretic Factor; D017923:Sodium-Hydrogen Exchangers; D010738:Type C Phospholipases; D000099242:Atrial Natriuretic Factor Receptor B; C091715:atrial natriuretic factor receptor A; C073616:atrial natriuretic factor receptor C; C039614:ethylisopropylamiloride